¼¼°èÀÇ HER2 À¯¹æ¾Ï °Ë»ç ½ÃÀå
HER2 Breast Cancer Tests
»óǰÄÚµå : 1798907
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 268 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

HER2 À¯¹æ¾Ï °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 5¾ï 2,950¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 3¾ï 9,440¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â HER2 À¯¹æ¾Ï °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 5¾ï 2,950¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 5.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¸é¿ªÁ¶Á÷È­ÇÐ °Ë»ç´Â CAGR 4.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 3¾ï 3,130¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Çü±¤/¹ß»ö In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç °Ë»ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 6.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 740¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ HER2 À¯¹æ¾Ï °Ë»ç ½ÃÀåÀº 2024³â¿¡ 1¾ï 740¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 410¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.8%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.5%¿Í 5.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ HER2 À¯¹æ¾Ï °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

HER2 À¯¹æ¾Ï °Ë»ç°¡ Çö´ë Á¾¾çÇп¡¼­ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

HER2(Human Epidermal Growth Factor Receptor 2) À¯¹æ¾Ï °Ë»ç´Â À¯¹æ¾Ï Á¶Á÷¿¡¼­ HER2 À¯ÀüÀÚÀÇ °ú¹ßÇö ¶Ç´Â ÁõÆøÀ» ÆÇ´ÜÇϱâ À§ÇØ »ç¿ëµÇ´Â Áø´Ü ÀýÂ÷ÀÔ´Ï´Ù. HER2 ¾ç¼º ¾ÏÀº ÀϹÝÀûÀ¸·Î Áõ½ÄÀÌ ºü¸£°í Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ ¹ÝÀÀµµ ´Ù¸£±â ¶§¹®¿¡ ÀÌ·¯ÇÑ °Ë»ç´Â Ä¡·á ¹æÄ§À» °áÁ¤ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Á¤È®ÇÑ ½Äº°À» ÅëÇØ Æ®¶ó½ºÅõÁÖ¸¿, ÆÛÅõÁÖ¸¿ µî HER2 Ȱ¼ºÀ» ƯÀÌÀûÀ¸·Î ¾ïÁ¦ÇÏ¿© »ýÁ¸ ¿¹Èĸ¦ °³¼±ÇÏ´Â Ä¡·á¹ýÀ» ¼±ÅÃÇÒ ¼ö ÀÖ½À´Ï´Ù.

°Ë»ç´Â ÀϹÝÀûÀ¸·Î »ý°Ë ¶Ç´Â ¼ö¼ú Á¶Á÷ »ùÇÃÀ» ÀÌ¿ëÇÑ ¸é¿ªÁ¶Á÷È­ÇÐ(IHC) ¶Ç´Â in situ hybridization(ISH) ±â¼úÀ» ÅëÇØ ÀÌ·ç¾îÁý´Ï´Ù. ÃÖ±Ù Áø´Ü Á¤È®µµ¸¦ ³ôÀ̱â À§ÇØ Ã·´Ü ºÐ¼®¹ý, µðÁöÅÐ º´¸®ÇÐÀû ¼Ö·ç¼Ç, µ¿¹ÝÁø´Ü ¾àǰÀÌ µîÀåÇϰí ÀÖ½À´Ï´Ù. HER2 °Ë»ç´Â ÇöÀç Á¾¾ç¼¾ÅÍÀÇ À¯¹æ¾Ï Áø´Ü ·çƾÀÇ ÀϺηΠÀÚ¸® Àâ¾ÒÀ¸¸ç, ÀÌ´Â °íǰÁúÀÇ ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¾î¶² Áø´Ü Çõ½ÅÀÌ °Ë»çÀÇ Á¤È®¼º°ú º¸±Þ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀ¸·Î HER2 °Ë»çÀÇ ¹Î°¨µµ, ÀçÇö¼º, ÇØ¼® °¡´É¼ºÀº Çâ»óµÇ°í ÀÖ½À´Ï´Ù. IHC °Ë»ç´Â °­È­µÈ Ç×ü, ÀÚµ¿ ¿°»ö ½Ã½ºÅÛ, Ç¥ÁØÈ­µÈ äÁ¡ ¾Ë°í¸®ÁòÀ» ÅëÇØ ÁøÈ­ÇØ ¿Ô½À´Ï´Ù. µà¾ó ÇÁ·Îºê ISH °Ë»ç´Â ¸ðÈ£ÇÑ °æ¿ì È®½ÅÀ» ÁÖ°í, °æ°è ºÎÀ§ÀÇ HER2 ¹ßÇöÀ» ÇØ°áÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Çü±¤ ISH(FISH) ¹× ¹ß»ö ISH(CISH)´Â ¼¼Æ÷ ¼öÁØ¿¡¼­ À¯ÀüÀÚ ÁõÆøÀ» È®ÀÎÇÏ´Â µ¥ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

»õ·Î¿î Ç÷§ÆûÀº Áø´Ü ¿öÅ©Ç÷ο츦 °­È­Çϱâ À§ÇØ µðÁöÅÐ ¿µ»ó, AI Áö¿ø º´¸®, ¸ÖƼÇ÷º½º °Ë»ç ±â´ÉÀ» ÅëÇÕÇÏ¿© Áø´Ü ¿öÅ©Ç÷ο츦 °­È­ÇÕ´Ï´Ù. ÀϺΠHER2 ºÐ¼®Àº ¿©·¯ ¹ÙÀÌ¿À¸¶Ä¿¸¦ µ¿½Ã¿¡ Æò°¡ÇÏ´Â ±¤¹üÀ§ÇÑ À¯Àüü ÇÁ·ÎÆÄÀϸµ °Ë»çÀÇ ÀϺηΠ°³¹ßµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ HER2¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â Ä¡·á°¡ À§¾Ï, ´ëÀå¾Ï µî ´Ù¸¥ ¾ÏÁ¾À¸·Î È®´ëµÇ¸é¼­ Ç¥Àû Ä¡·áÁ¦¿Í ÇÔ²² °øµ¿ °³¹ßµÈ µ¿¹ÝÁø´Ü °Ë»çµµ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù.

°Ë»ç·®Àº ¾îµð¿¡¼­ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¾î¶² ½Ã¼³ÀÌ º¸±ÞÀ» ÁÖµµÇϰí Àִ°¡?

À¯¹æ¾Ï ¹ßº´·üÀÇ Áõ°¡¿Í Á¾¾çÇп¡¼­ ¸ÂÃãÇü ÀÇ·áÀÇ µµÀÔÀÌ È®´ëµÊ¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î °Ë»ç·®ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. º´¿ø, ¾ÏÀü¹®¼¾ÅÍ, Ç¥Áذ˻ç½ÇÀÌ ÁÖ¿ä °Ë»ç½Ã¼³ÀÔ´Ï´Ù. °í¼Òµæ ±¹°¡¿¡¼­´Â HER2 °Ë»ç°¡ À¯¹æ¾Ï °ËÁøÀÇ Ç¥ÁØ °Ë»ç Ç׸ñÀ̸ç, Áß»êÃþ Áö¿ª¿¡¼­´Â º´¸®ÇÐÀû ÀÎÇÁ¶ó¿Í Ä¡·á Á¢±Ù¼º Çâ»óÀ¸·Î ÀÎÇØ °Ë»ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

ºÏ¹Ì¿Í À¯·´Àº Áø´Ü °¡À̵å¶óÀΰú »óȯÁ¦µµ°¡ È®¸³µÈ ¼º¼÷ÇÑ ½ÃÀåÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº À¯¹æ¾Ï¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í, Ç¥Àû Ä¡·á Á¢±Ù¼º È®´ë, Á¤ºÎÀÇ ¾Ï Áø´Ü¾à Áö¿ø Á¤Ã¥ µîÀ¸·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¹Î°ü Çù·Â°ú Àü±¹ÀûÀÎ ¾Ï °ËÁø ÇÁ·Î±×·¥ °³¹ßÀº °ËÁø º¸±ÞÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

HER2 À¯¹æ¾Ï °Ë»ç ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

HER2 À¯¹æ¾Ï °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è À¯¹æ¾Ï ¹ßº´·ü Áõ°¡, HER2 Ç¥Àû Ä¡·áÁ¦ »ç¿ë Áõ°¡, Áø´Ü Á¤È®µµÀÇ Áö¼ÓÀûÀÎ Çâ»ó µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¿°»ö ½Ã¾à, ÀÚµ¿È­ ½Ã½ºÅÛ, AI¸¦ žÀçÇÑ º´¸®°Ë»ç µµ±¸ÀÇ ¹ßÀüÀ¸·Î HER2 °Ë»çÀÇ Á¤È®¼º°ú È®À强ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

¾Ï Àü¹®º´¿ø, º´¸®°Ë»ç½Ç, HER2 Ç¥Àû ½Å¾àÀÇ µ¿¹ÝÁø´Ü¿¡ ´ëÇÑ ÃÖÁ¾ ¿ëµµ È®´ë°¡ ½ÃÀåÀÇ °ü·Ã¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. À¯¹æ¾Ï ÀÌ¿ÜÀÇ Á¾¾ç À¯Çü¿¡¼­ HER2 °Ë»çÀÇ ±ÔÁ¦ ½ÂÀΰú ¸ÖƼÇ÷º½º ¹ÙÀÌ¿À¸¶Ä¿ ÆÐ³ÎÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ±× Àû¿ë ¹üÀ§°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á°¡ Á¾¾ç Ä¡·áÀÇ Áß½ÉÀÌ µÊ¿¡ µû¶ó, ½Å·ÚÇÒ ¼ö ÀÖ´Â °í󸮷® HER2 °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â ²ÙÁØÈ÷ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

°Ë»ç À¯Çü(¸é¿ªÁ¶Á÷È­ÇÐ °Ë»ç, Çü±¤/¹ß»ö In-Situ ÇÏÀ̺긮´ÙÀÌÁ¦ÀÌ¼Ç °Ë»ç), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, Áø´Ü ½ÇÇè½Ç ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global HER2 Breast Cancer Tests Market to Reach US$529.5 Million by 2030

The global market for HER2 Breast Cancer Tests estimated at US$394.4 Million in the year 2024, is expected to reach US$529.5 Million by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Immunohistochemistry Test, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$331.3 Million by the end of the analysis period. Growth in the Fluorescence / Chromogenic In-Situ Hybridization Test segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$107.4 Million While China is Forecast to Grow at 7.8% CAGR

The HER2 Breast Cancer Tests market in the U.S. is estimated at US$107.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$104.1 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global HER2 Breast Cancer Tests Market - Key Trends & Drivers Summarized

Why Are HER2 Breast Cancer Tests Essential in Modern Oncology?

HER2 (Human Epidermal Growth Factor Receptor 2) breast cancer tests are diagnostic procedures used to determine the overexpression or amplification of the HER2 gene in breast cancer tissue. These tests are critical in guiding treatment decisions, as HER2-positive cancers typically grow faster and respond differently to targeted therapies. Accurate identification allows for the selection of therapies such as trastuzumab or pertuzumab, which specifically inhibit HER2 activity and improve survival outcomes.

Testing is typically performed using immunohistochemistry (IHC) or in situ hybridization (ISH) techniques on biopsy or surgical tissue samples. In recent years, advanced assays, digital pathology solutions, and companion diagnostics have emerged to improve diagnostic precision. HER2 testing is now a routine part of breast cancer diagnosis in oncology centers, contributing to the growing demand for high-quality and reliable diagnostic platforms.

What Diagnostic Innovations Are Influencing Test Accuracy and Adoption?

Technological advancements have improved HER2 test sensitivity, reproducibility, and interpretability. IHC tests have evolved with enhanced antibodies, automated staining systems, and standardized scoring algorithms. Dual-probe ISH tests provide confirmation in ambiguous cases, helping resolve borderline HER2 expressions. Fluorescence ISH (FISH) and chromogenic ISH (CISH) remain widely used for confirming gene amplification at the cellular level.

Emerging platforms are integrating digital imaging, AI-assisted pathology, and multiplex testing capabilities to enhance diagnostic workflows. Some HER2 assays are now being developed as part of broader genomic profiling tests that assess multiple biomarkers simultaneously. Companion diagnostic tests co-developed with targeted drugs are also gaining traction, especially as HER2-targeted treatments expand into other tumor types like gastric and colorectal cancers.

Where Is Testing Volume Increasing, and Which Institutions Are Driving Uptake?

Testing volumes are rising globally due to increasing breast cancer incidence and the growing adoption of personalized medicine in oncology. Hospitals, cancer specialty centers, and reference laboratories are key testing sites. In high-income countries, HER2 testing is a standard part of breast cancer workups, while in middle-income regions, uptake is increasing with improvements in pathology infrastructure and treatment access.

North America and Europe are mature markets with well-established diagnostic guidelines and reimbursement systems. Asia Pacific is witnessing rapid growth due to rising breast cancer awareness, expanding access to targeted therapies, and government initiatives supporting oncology diagnostics. The development of public-private partnerships and national cancer screening programs is further accelerating testing penetration.

What Is Driving Growth in the HER2 Breast Cancer Tests Market?

Growth in the HER2 breast cancer tests market is driven by several factors including rising global breast cancer incidence, increased use of HER2-targeted therapies, and ongoing improvements in diagnostic precision. Advances in staining reagents, automation systems, and AI-powered pathology tools are making HER2 testing more accurate and scalable.

End-use expansion in oncology hospitals, pathology labs, and companion diagnostics for new HER2-targeted drugs is boosting market relevance. Regulatory approvals for HER2 testing in tumor types beyond breast cancer and increased adoption of multiplex biomarker panels are broadening application scope. As precision medicine becomes central to oncology care, demand for reliable, high-throughput HER2 testing solutions is expected to grow steadily.

SCOPE OF STUDY:

The report analyzes the HER2 Breast Cancer Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Immunohistochemistry Test, Fluorescence / Chromogenic In-Situ Hybridization Test); End-User (Hospitals End-User, Diagnostic Laboratories End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â